Technical Analysis for ARDS - Aridis Pharmaceuticals Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 20 DMA | Bullish | -10.08% | |
Inside Day | Range Contraction | -10.08% | |
Up 3 Days in a Row | Strength | -10.08% | |
20 DMA Resistance | Bearish | -6.33% | |
Shooting Star Candlestick | Bearish | -6.33% | |
Lizard Bearish | Bearish Day Trade Setup | -6.33% | |
180 Bearish Setup | Bearish Swing Setup | -6.33% | |
Narrow Range Bar | Range Contraction | -4.75% | |
Inside Day | Range Contraction | -4.75% | |
Wide Bands | Range Expansion | -4.75% |
Alert | Time |
---|---|
Rose Above Upper Bollinger Band | about 19 hours ago |
20 DMA Resistance | about 19 hours ago |
10 DMA Resistance | about 19 hours ago |
1.5x Volume Pace | about 19 hours ago |
Down 5% | about 19 hours ago |
Get a Trading Sidekick!
- Earnings date: 06/06/2024
Aridis Pharmaceuticals Inc. Description
Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs), to treat infections. mAbs represents treatment approach that enables the human immune system to fight infections and are designed to overcome the deficiencies associated with current therapies, such as rise in drug resistance, short duration of response, negative impact on the human microbiome, and lack of differentiation among the treatment alternatives. Its product pipeline comprises of human mAbs targeting specific pathogens associated with bacterial infections, primarily hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). Its lead product candidate, AR-301 targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus, a common pathogen associated with HAP and VAP. Its AR-101 (Aerumab) is a fully human immunoglobulin M, mAb targeting P. aeruginosa serotype O11.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Immune System Immunotherapy Infectious Diseases Antibodies Monoclonal Antibodies Monoclonal Antibody Infection Bacterial Infections Bacterial Disease Staphylococcus Aureus Human Monoclonal Antibodies Pathogenic Bacteria Drug Resistance Pneumonia Pseudomonas Aeruginosa Targeted Immunotherapy Immunoglobulin M
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 0.5395 |
52 Week Low | 0.05 |
Average Volume | 59,272 |
200-Day Moving Average | 0.09 |
50-Day Moving Average | 0.07 |
20-Day Moving Average | 0.06 |
10-Day Moving Average | 0.06 |
Average True Range | 0.01 |
RSI (14) | 47.37 |
ADX | 18.31 |
+DI | 18.51 |
-DI | 13.67 |
Chandelier Exit (Long, 3 ATRs) | 0.06 |
Chandelier Exit (Short, 3 ATRs) | 0.08 |
Upper Bollinger Bands | 0.07 |
Lower Bollinger Band | 0.06 |
Percent B (%b) | 0.52 |
BandWidth | 22.19 |
MACD Line | 0.00 |
MACD Signal Line | 0.00 |
MACD Histogram | 0.0004 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.07 | ||||
Resistance 3 (R3) | 0.07 | 0.07 | 0.07 | ||
Resistance 2 (R2) | 0.07 | 0.07 | 0.07 | 0.07 | |
Resistance 1 (R1) | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 |
Pivot Point | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 |
Support 1 (S1) | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 |
Support 2 (S2) | 0.06 | 0.06 | 0.06 | 0.05 | |
Support 3 (S3) | 0.05 | 0.06 | 0.05 | ||
Support 4 (S4) | 0.05 |